


Asian firms lack antibody manufacturing capabilities

04 October 2012 | Analysis | By BioSpectrum Bureau

Asian firms lack antibody manufacturing capabilities



There are very few manufacturers in Asia capable of manufacturing antibodies on a large commercial scale. Manufacturing facilities for antibodies require substantial capital investments and competencies and while Asian companies have technologies of global standard, they don't have extensive experience in cGMP or euGMP. This proves a hurdle for them in meeting standards for international regulatory approvals.

India-based Reliance Life Science is one of the few biologics companies manufacturing antibodies at a large scale. However, many companies in Asia choose to outsource manufacturing activities in the absence of required infrastructure.

Mr K V Subramaniam, president and CEO, Reliance Life Sciences, said that monoclonal antibodies are complex biological compounds and cell line engineering is a major challenge. "Further, dosage for these products is much higher compared to

other recombinant proteins. The production requirements are consequently higher. As a result, investment in large-scale manufacturing facilities for production of antibodies is an imperative and having the requisite competencies."

Reliance Life Science has built a large commercial-scale antibody manufacturing facility, which is approved by the European Medical Agency, National Health Surveillance Agency (ANVISA) and other international regulatory agencies. The company has also produced several monoclonal antibodies at large scale for clinical trials.

Mr Jin San Yoo, CEO, PharmAbcine, says his company is outsourcing its clinical sample manufacturing for approval from the Korean FDA. For the China market too, the company has to manufacture preclinical and clinical samples in China. PharmAbcine is looking for a local Chinese company with its own manufacturing facility in the country or at least one that can manage the manufacturing issue in China.

Taiwan-based Abnova has set up GMP compliant manufacturing facility to produce analyte-specific reagents to initiate clinical trial for in vitro diagnostic for lung cancer. "Antibodies are being humanized to create the lead drug antibody candidate for treatment of prostate cancer and other ailments and antibody manufacturing capability will enable us to achieve the goals efficiently," said Mr Wilber Huang, president and CEO of Abnova.

Each country in Asia has its own limitations and cooperation between them plays a significant role in the antibodies that emerge from research in Asia. For example, Singapore has the capabilities in R&D for creating innovative drugs. South Korea has manufacturing capabilities and other Asian countries have improved its clinical development capabilities in the past few years. Therefore, if these strengths are combined, it will gain capabilities to generate antibodies in this region.

As the industry is witnessing fewer breakthroughs in the discovery of new drugs amid the increase in R&D expenditure, focus on antibodies research is increasing. Though the biotech manufacturing infrastructure in Asia has been expanding steadily, there are few who have received global regulatory approvals, especially from developed markets such as the US and Europe, and have the necessary experience to service these markets.